Latest News - Genentech

Wednesday, October 05, 2016 | Clinical Trials, Genentech

FDA Grants Breakthrough Therapy Designation for Actemra in Giant Cell Arteritis

Genentech announced today that the FDA has granted breakthrough therapy designation status to Actemra (tocilizumab) for giant cell arteritis (GCA), a chronic, potentially life-threatening autoimmune c…

Read the full story

Wednesday, June 08, 2016 | Clinical Trials, Genentech

Phase 3 Study Shows Genentech's Actemra (Tocilizumab) Maintained Steroid-Free Remission in People with Giant Cell Arteritis

Genentech announced positive results from the phase 3 study known as GiACTA, which evaluated Actemra (tocilizumab) in people with giant cell arteritis (GCA), according to a company news release. The s…

Read the full story

Monday, May 02, 2016 | Medical Studies, Retina, Genentech

Five-Year Outcomes of CATT Study Comparing Anti-VEGF Agents for Treatment of AMD Released

The National Eye Institute’s CATT (Comparison of Age-related Macular Degeneration Treatments Trial) study was a 2-year study that compared the relative safety and effectiveness of Lucentis (rani…

Read the full story

Sunday, February 28, 2016 | Clinical Trials, Retina, Genentech, Regeneron Pharmaceuticals

Protocol T: 2-Year Data Released

All three anti-VEGF agents evaluated in the Diabetic Retinopathy Clinical Research Network (DRCR.net) Protocol T trial were effective in treating diabetic macular edema (DME) at 2 years, according to …

Read the full story

Wednesday, November 18, 2015 | Earnings & Financials, Retina, Genentech, Ophthotech, Roche

Genentech Elects to Exercise Its Right to Opt-in to the Novartis Portion of the Ophthotech/Novartis Ex-US Agreement for Fovista to Treat Wet AMD

Ophthotech announced that Genentech has elected to exercise its option to participate in the financial arrangements relating to Novartis’ rights under the Ophthotech/Novartis ex-US agreement for…

Read the full story

Friday, November 13, 2015 | Medical Studies, Genentech

DRCR.net: Lucentis Effective for Proliferative Diabetic Retinopathy

A clinical trial funded by the National Institutes of Health has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy, according to a National …

Read the full story

Monday, October 12, 2015 | Clinical Trials, Genentech

Genentech Completes Phase 3 Enrollment for Giant Cell Arteritis Trial

Genentech has announced the completion of enrollment for a phase 3 clinical trial investigating the use of Actemra (tocilizumab) in patients with giant cell arteritis (GCA). The data from the trial (N…

Read the full story

Friday, August 14, 2015 | Medical Studies, Retina, Genentech

Fears Of Potentially Blinding Complication From Avastin Eye Injections Are Overblown, According to Penn Study

Eye injections of the drug Avastin, used to treat retinal diseases, bring no greater risk of endophthalmitis, a potentially blinding eye infection, than injections with the much more expensive drug Lu…

Read the full story

Monday, February 09, 2015 | FDA Approval/Clearance, Genentech

FDA Approves Lucentis for Treatment of Diabetic Retinopathy in People with Diabetic Macular Edema

Genentech announced that the FDA has approved Lucentis (ranibizumab) for the treatment of diabetic retinopathy (DR) in people with diabetic macular edema (DME), according to a company news release. Th…

Read the full story

Monday, December 15, 2014 | Retina, Genentech

FDA Grants Breakthrough Therapy Designation for Lucentis for the Treatment of Diabetic Retinopathy

The FDA has granted breakthrough therapy designation for Lucentis (ranibizumab; Genentech) for the treatment of diabetic retinopathy, according to a company statement. A medicine may be designated …

Read the full story